The United States Food and Drug Administration (FDA) approved Auvelity (dextromethorphan HBr-bupropion HCl) in October 2023 for the treatment of major depressive disorder (MDD) in adults [1]. The drug's active ingredients are dextromethorphan and bupropion [1].
What is Auvelity used for?
Auvelity is indicated for the treatment of major depressive disorder (MDD) in adults [1].
How does Auvelity work?
Auvelity combines dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor [1]. This dual mechanism is believed to modulate glutamatergic and aminergic neurotransmission, which are implicated in depression [1].
When was Auvelity approved in the US?
The FDA approved Auvelity in October 2023 [1].
Is Auvelity registered in Poland?
Information regarding the registration status of Auvelity in Poland is not available in the provided text. The approval mentioned is specific to the United States FDA [1].
What are the active ingredients in Auvelity?
Auvelity contains dextromethorphan hydrobromide and bupropion hydrochloride as its active ingredients [1].
What are the potential side effects of Auvelity?
Common side effects of Auvelity can include dizziness, headache, diarrhea, insomnia, and nausea [1]. Serious side effects may involve suicidal thoughts and behaviors, and the risk of seizures [1].
What is the recommended dosage for Auvelity?
The recommended starting dose for Auvelity is one tablet (6 mg dextromethorphan HBr/45 mg bupropion HCl) taken orally once daily in the morning for three days, followed by one tablet taken orally twice daily (morning and evening) thereafter [1].
What drugs should not be taken with Auvelity?
Auvelity should not be used in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI [1]. It also has significant drug interactions with bupropion, CYP2D6 inhibitors and inducers, and other medications [1].
What is the difference between Auvelity and other depression medications?
Auvelity's unique combination of dextromethorphan and bupropion offers a novel mechanism of action compared to traditional antidepressants that primarily target serotonin or norepinephrine [1]. Dextromethorphan acts as an NMDA receptor antagonist, while bupropion inhibits the reuptake of norepinephrine and dopamine [1].
Are there clinical trials supporting Auvelity's efficacy?
The efficacy of Auvelity was established in two randomized, double-blind, placebo-controlled trials in adults with MDD [1]. In these trials, Auvelity demonstrated statistically significant improvements in depressive symptoms compared to placebo [1].
Where can I find more information about Auvelity patents?
Information on drug patents, including those related to Auvelity, can be found on specialized databases. For example, DrugPatentWatch.com provides a resource for patent information [2].